News

This is the first of what the Company expects will be a series of product acquisitions designed to generate revenue and strengthen its financial position. Vivus CEO John

The collaboration utilises both companies’ drug discovery technologies, in particular C4XD’s Taxonomy3 novel target identification platform and ETX’s Network-driven Drug Discovery (NDD) capabilities. Teams from both companies will

The new indication approved by the US Food and Drug Administration (FDA) covers diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma and DLBCL. The immunocellular therapy has

The application seeks approval for KEYTRUDA in combination with pemetrexed (ALIMTA) and platinum chemotherapy (carboplatin or cisplatin) as a first-line treatment for patients with metastatic nonsquamous non-small cell

PHN is the licensor of Gleolan (aminolevulinic acid HCl (ALA)) to NXDC. The companies share an eight-year working relationship. PHN is engaged in the development of drugs that

The ORR, which was the primary objective of the STORM trial, included two complete responses (CRs) and 29 partial (PRs) or very good partial responses (VGPRs) across patients with

The deal is the consequence of a divestiture process mandated by the Federal Trade Commission (FTC) in association with Amneal Pharmaceutical’s proposed business combination with Impax Laboratories. Under

The companies are partners on a grant titled, "A novel small molecule approach to enhance cancer immunotherapy." Their research plan proposes to develop small-molecule drugs that will stimulate

The recommendation is based on results from the Phase III FLAURA trial, which were presented at the European Society of Medical Oncology 2017 Congress and published in the New